Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs

[1]  D. Waisman,et al.  RNA Interference-mediated Silencing of the S100A10 Gene Attenuates Plasmin Generation and Invasiveness of Colo 222 Colorectal Cancer Cells* , 2004, Journal of Biological Chemistry.

[2]  E. Bröcker,et al.  Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation , 2003, Molecular and Cellular Biology.

[3]  H. Wajant,et al.  Selective Inhibition of FLICE-like Inhibitory Protein (FLIP) Expression With Small Interfering RNA Oligonucleotides (siRNAs) Is Sufficient to Sensitize Tumor Cells for TRAIL-Induced Apoptosis , 2002 .

[4]  G. Cohen,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia , 2002, Oncogene.

[5]  A. Grosse-Wilde,et al.  Caspase‐10 is recruited to and activated at the native TRAIL and CD95 death‐inducing signalling complexes in a FADD‐dependent manner but can not functionally substitute caspase‐8 , 2002, The EMBO journal.

[6]  E. Borden,et al.  Identification of X-linked Inhibitor of Apoptosis-associated Factor-1 as an Interferon-stimulated Gene That Augments TRAIL Apo2L-induced Apoptosis* , 2002, The Journal of Biological Chemistry.

[7]  Xiaolu Yang,et al.  c‐FLIPL is a dual function regulator for caspase‐8 activation and CD95‐mediated apoptosis , 2002, The EMBO journal.

[8]  Sunshin Kim,et al.  Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis , 2002, Oncogene.

[9]  S. Fulda,et al.  Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression , 2002, Oncogene.

[10]  J. Herman,et al.  Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. , 2002, Cancer research.

[11]  K. Tyler,et al.  TRAIL and inhibitors of apoptosis are opposing determinants for NF-κB-dependent, genotoxin-induced apoptosis of cancer cells , 2002, Oncogene.

[12]  H. Shu,et al.  The short splice form of Casper/c‐FLIP is a major cellular inhibitor of TRAIL‐induced apoptosis , 2002, FEBS letters.

[13]  J. Blenis,et al.  Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8* , 2001, The Journal of Biological Chemistry.

[14]  G. Gores,et al.  The Bile Acid Glycochenodeoxycholate Induces TRAIL-Receptor 2/DR5 Expression and Apoptosis* , 2001, The Journal of Biological Chemistry.

[15]  P. Hersey,et al.  Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. , 2001, Cancer research.

[16]  G. Cohen,et al.  Modulation of Tumor Necrosis Factor Apoptosis-inducing Ligand- induced NF-κB Activation by Inhibition of Apical Caspases* , 2001, The Journal of Biological Chemistry.

[17]  Z. Wang,et al.  Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.

[18]  B. Vandenbunder,et al.  Rel/NF-κB Transcription Factors Protect against Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Up-regulating the TRAIL Decoy Receptor DcR1* , 2001, The Journal of Biological Chemistry.

[19]  Shi-Yong Sun,et al.  Evidence that the death receptor DR4 is a DNA damage‐inducible, p53‐regulated gene , 2001, Journal of cellular physiology.

[20]  G. Gores,et al.  Is TRAIL hepatotoxic? , 2001, Hepatology.

[21]  H. Walczak,et al.  Biochemistry and function of the DISC. , 2001, Trends in biochemical sciences.

[22]  P. Krammer,et al.  Cellular FLICE-inhibitory Protein Splice Variants Inhibit Different Steps of Caspase-8 Activation at the CD95 Death-inducing Signaling Complex* , 2001, The Journal of Biological Chemistry.

[23]  M. Nau,et al.  Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. , 2001, Gynecologic oncology.

[24]  R. K Srivastava,et al.  Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways , 2001, Oncogene.

[25]  C. Belka,et al.  Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL , 2001, Oncogene.

[26]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.

[27]  Erwin G. Van Meir,et al.  Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. , 2001, Cancer research.

[28]  L. Corcos,et al.  Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. , 2001, Cancer research.

[29]  K. Bhalla,et al.  Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. , 2000, Blood.

[30]  P. Krammer,et al.  TCR-Mediated Up-Regulation of c-FLIPshort Correlates with Resistance Toward CD95-Mediated Apoptosis by Blocking Death-Inducing Signaling Complex Activity1 , 2000, The Journal of Immunology.

[31]  P. Hersey,et al.  TNF-Related Apoptosis-Inducing Ligand-Induced Apoptosis of Melanoma Is Associated with Changes in Mitochondrial Membrane Potential and Perinuclear Clustering of Mitochondria1 , 2000, The Journal of Immunology.

[32]  J. Soria,et al.  TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer. , 2000, Anticancer research.

[33]  P. Krammer,et al.  CD95's deadly mission in the immune system , 2000, Nature.

[34]  P. Hersey,et al.  Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types , 2000, FEBS letters.

[35]  A. Fornace,et al.  Death and decoy receptors and p53-mediated apoptosis , 2000, Leukemia.

[36]  R. K Srivastava.  Intracellular mechanisms of TRAIL and its role in cancer therapy. , 2000, Molecular cell biology research communications : MCBRC.

[37]  D. Lawrence,et al.  Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. , 2000, Immunity.

[38]  J. Blenis,et al.  FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. , 2000, Immunity.

[39]  P. Krammer,et al.  Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. , 2000, Cancer research.

[40]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.

[41]  J. Tschopp,et al.  TRAIL receptor-2 signals apoptosis through FADD and caspase-8 , 2000, Nature Cell Biology.

[42]  W. Cavenee,et al.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. , 2000, Cancer research.

[43]  E. Bröcker,et al.  Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. , 2000, Cancer research.

[44]  B. Gliniak,et al.  Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. , 1999, Cancer research.

[45]  J. Houghton.  Apoptosis and drug response. , 1999, Current opinion in oncology.

[46]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[47]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[48]  Ingo Schmitz,et al.  The Role of c-FLIP in Modulation of CD95-induced Apoptosis* , 1999, The Journal of Biological Chemistry.

[49]  P. Galle,et al.  The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis. , 1999, European cytokine network.

[50]  T. Griffith,et al.  Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. , 1998, Journal of immunology.

[51]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[52]  A. Fornace,et al.  p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. , 1998, Cancer research.

[53]  V. Dixit,et al.  TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling , 1998, FEBS letters.

[54]  J. Bell,et al.  Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. , 1998, Journal of immunology.

[55]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[56]  M. Peter,et al.  FLICE Is Predominantly Expressed as Two Functionally Active Isoforms, Caspase-8/a and Caspase-8/b* , 1997, The Journal of Biological Chemistry.

[57]  S. Srinivasula,et al.  Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL* , 1997, The Journal of Biological Chemistry.

[58]  R. Dubose,et al.  Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family , 1997, The Journal of experimental medicine.

[59]  M. Kastan.  On the TRAIL from p53 to apoptosis? , 1997, Nature Genetics.

[60]  J. Bell,et al.  TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL , 1997, Current Biology.

[61]  Henning Walczak,et al.  TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.

[62]  W I Wood,et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.

[63]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[64]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[65]  J. Tschopp,et al.  Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors , 1997, Nature.

[66]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[67]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[68]  Michael Weller,et al.  Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.

[69]  H. Wajant,et al.  Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. , 2002, Molecular medicine.

[70]  Yahong Lin,et al.  TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. , 2002, Genes & development.

[71]  山中 猛成.  Chemotherapeutic Agents Augment TRAIL-Induced Apoptosis in Human Hepatocellular Carcinoma Cell Lines , 2001 .

[72]  M. Peter,et al.  The death receptors. , 1999, Results and problems in cell differentiation.

[73]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[74]  J. Tschopp,et al.  Characterization of two receptors for TRAIL. , 1997, FEBS letters.